Welcome to the Oncology Brothers podcast! In this episode, we dived into a challenging case series focused on kidney cancer, featuring special guest Dr. Pedro Barata, a GU medical oncologist from the University Hospitals.

We had the opportunity to explore two real-life cases that highlighted the complexities of treatment decisions in metastatic renal cell carcinoma (RCC). We discussed the latest frontline options, including immunotherapy and targeted therapy combinations, and how to choose the best approach based on patient characteristics and disease progression.

Key topics covered in this episode included:

The role of next-generation sequencing (NGS) in guiding treatment options
Choosing between dual checkpoint inhibitors and IO-TKI combinations
Managing side effects associated with various treatment regimens
Sequencing treatment options for patients who progress after initial therapy
Insights into the latest data on emerging therapies like Belzutifan and Lenvatinib

Listen us on:

Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:

Don't forget to like, subscribe, and check out our other episodes for more challenging case discussions and treatment algorithms!

#KidneyCancer, #RenalCellCarcinoma, #RCC, #Immunotherapy, #TKI, #OncologyBrothers

Challenging Cases - Treatment of Relapsed / Refractory Renal Cell Carcinoma (RCC): Dr. Pedro Barata

Oncology Brothers: Practice-Changing Cancer Discussions

Challenging Cases - Treatment of Relapsed / Refractory Renal Cell Carcinoma (RCC): Dr. Pedro Barata